 |
| Site navigation |
|
|
|
| Conferences, Seminars and Workshops |
IACMAC activity plan for 2018-2019
- Eurasian Congress on Antimicrobial Therapy and Clinical Microbiology (October 17–18, 2019, Ufa)
- Certification workshop of professional education on specialty “Bacteriology” (October 21 – November 22, 2019, Smolensk)
|
Online course “Antimicrobial Stewardship: Managing Antibiotic Resistance”
You are invited to participate in Massive Open Online Course (MOOC) in Russian. This educational course was developed by Dundee University, the British Society for Antimicrobial Chemotherapy (BSAC) and the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC). |
|
| Studies |
Dear colleagues! We encourage to take part in multicenter prospective microbiological study of the antimicrobial resistance of community-acquired pathogens: S. pneumoniae, H. influenzae and S. pyogenes (PeGAS study). |
Since 2015 IAC and IACMAC have conducted multicenter study aimed to evaluate the prevalence of mutation resistance to macrolide antibiotic in Mycoplasma pneumonia and Mycoplasma genitalium. |
|
| Website News |
European Committee on Antimicrobial Susceptibility Testing (EUCAST) has amended the clinical classification of susceptibility (categories S,I and R): currently the clinical evaluation of susceptibility is connected with drug exposure in the nidus of infection. |
The occupational standard on specialty "Medical microbiology" from the Ministry of Healthcare of the Russian Federation is posted on IACMAC website. |
Clinical guidelines on diagnostics and treatment of community-acquired pneumonia in adults.
The Russian Respiratory Society (RRC) and the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC) have published for discussion the clinical guidelines on diagnostics and treatment of community-acquired pneumonia in adults. |
Clinical guidelines “Mucoviscidosis: microbiological diagnostics of chronic respiratory infection” |
Clinical guidelines on antimicrobial susceptibility testing, approved at the IACMAC extended session in Moscow are posted on the website.
Clinical guidelines on isolation, identification and antimicrobial susceptibility of Helicobacter pylori are added. |
|
| New Articles |
|
|
|
| Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired resistance mechanisms. |
Mar 18, 2019 - 10:15 |
|
|
|
| Azithromycin significantly reduces the risk of BPD in preterm neonates. The relationship between azithromycin and IHPS requires further investigation. |
Mar 06, 2019 - 10:20 |
|
|
|
| Addition of S. boulardii to sequential therapy improved H. pylori eradication rate and reduced the incidence of treatment-associated AEs in Moroccan patients with H. pylori infection. |
Mar 05, 2019 - 10:15 |
|
|
|
| Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation Against Pneumonia (LEAP 1) study (NCT02559310) was a global noninferiority trial to evaluate the efficacy and safety of lefamulin for the treatment of CABP. |
Mar 01, 2019 - 13:40 |
|
|
|
| Infectious spondylodiscitis is an infectious disease that is rare and difficult to diagnose due to its non-specific clinical features. In this study, we aimed to describe the clinical and diagnostic features of infectious spondylodiscitis. |
Feb 28, 2019 - 14:20 |
|
|
|
| According to Merck, the agency accepted an NDA for priority review for a combination of relebactam, an investigational beta-lactamase inhibitor, with imipenem/cilastatin (MK-7655A, IMI/REL) for the treatment of complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) caused by certain susceptible gram-negative bacteria for adults who have limited or no alternative therapies. |
Feb 25, 2019 - 00:53 |
|
|
|
| “Strep throat” is highly prevalent among children, yet it is unknown why only some children develop recurrent tonsillitis (RT), a common indication for tonsillectomy. To gain insights into this classic childhood disease, we performed phenotypic, genotypic, and functional studies on pediatric group A Streptococcus (GAS) RT and non-RT tonsils from two independent cohorts. |
Feb 14, 2019 - 14:20 |
|
|
|
| Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the FDA of its Investigational New Drug (IND) application for SPR994, Spero’s lead product candidate designed to be the first oral carbapenem antibiotic, for the treatment of complicated urinary tract infections (cUTI). |
Feb 12, 2019 - 11:45 |
|
|
|
| Randomised controlled trials (RCTs) of vitamin D to prevent COPD exacerbations have yielded conflicting results. Individual participant data meta-analysis could identify factors that explain this variation. |
Jan 28, 2019 - 14:10 |
|
|
|
| Streptococcus salivarius K12 (SsK12) appears safe and well-tolerated, however further RCTs are required to establish its role as a prophylactic therapy, particularly amongst patients experiencing frequent exacerbations of pharyngitis. In the acute setting, SsK12 is unlikely to be effective if given concurrently with antibiotics, however further RCTs should establish its role as an alternative to antibiotics in non-severe cases, or when prescribed post-antibiotic therapy for the prevention of disease recurrence and/or secondary infection. |
Jan 24, 2019 - 14:20 |
|
|
